CagriSema meta-analysis of six trials reports larger weight loss than semaglutide in type 2 diabetes

This source is a systematic review and Bayesian meta-analysis of randomized controlled trials in humans, covering six trials that represented 4554 potentially eligible participants with Type 2 diabetes. CagriSema combines cagrilintide with semaglutide, and the authors state they evaluated its dose- and comparator-specific efficacy and safety.

The authors report searching PubMed, Embase, CENTRAL and ClinicalTrials.gov through 30 June 2026. Analyses were stratified by CagriSema dose and comparator. For HbA1c and body weight, efficacy/trial-product estimands were aligned where sufficiently reported, with treatment-policy estimates examined in sensitivity analyses, and Bayesian random-effects models generated posterior medians and 95% credible intervals.

Compared with placebo, the pooled analysis reports between-group differences of -1.87 percentage points in HbA1c (95% CrI, -2.08 to -1.62) and -12.69 percentage points in percentage body-weight change (95% CrI, -13.78 to -11.61) for the higher CagriSema dose arm.

Versus dose-matched semaglutide, the authors describe the additional HbA1c reduction as modest and uncertain (-0.21 percentage points; 95% CrI, -0.62 to 0.11), while the additional body-weight reduction remained probable (-5.84 percentage points; 95% CrI, -10.08 to -2.15).

On safety, gastrointestinal adverse events and adverse-event-related discontinuation were increased versus placebo (RR, 2.27 [95% CrI, 1.81 - 3.00] and 3.16 [1.50 to 6.87], respectively), while estimates versus semaglutide were less precise.

The abstract reports pooled estimates by dose. The CagriSema arm analysed against placebo and against the active comparator was the 2.4 mg dose in participants with Type 2 diabetes, and the active comparator arm was semaglutide at the same stated dose. The abstract does not report injection schedules, titration steps, treatment duration, or route for these arms.

This is a pooled analysis of six trials, not a new randomized experiment, so findings depend on how the included trials were conducted and reported. The abstract states that estimands were aligned only where sufficiently reported, which implies variation across trials.

The authors themselves report that the incremental advantage over dose-matched semaglutide is clearer for body weight than for HbA1c, and that comparative gastrointestinal tolerability and discontinuation risk remain uncertain. Credible intervals for the discontinuation comparison versus placebo were wide (1.50 to 6.87). The abstract does not state funding, author affiliations, trial-level risk of bias, or follow-up duration.

Cagrilintide, also referred to as AM833 or NNC0174-0833 and coformulated with semaglutide as CagriSema, is not an FDA-approved drug for any use. That status comes from the site's regulatory review, not from this publication.